期刊文献+

Altered miR-143 and miR-150 expressions in peripheral blood mononuclear cells for diagnosis of non-small cell lung cancer 被引量:13

Altered miR-143 and miR-150 expressions in peripheral blood mononuclear cells for diagnosis of non-small cell lung cancer
原文传递
导出
摘要 Background Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and reduce the mortality.Small non-coding microRNAs (miRNAs) are key components of cancer development and are considered as potential biomarkers for cancer diagnosis and for monitoring treatment.The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in peripheral blood mononuclear cells (PBMC) for the diagnosis of NSCLC.Methods The levels of two mature miRNAs (miR-143 and miR-150) were detected by probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in PBMC of 64 patients with NSCLC and 26 healthy individuals,and the relationship between miR-143 and miR-150 levels and clinical and pathological factors was explored.Results All endogenous miRNAs were present in peripheral blood in a remarkably stable form and detected by RT-qPCR.MiR-143 expression in the PBMC specimens was significantly lower in NSCLC patients than in healthy individuals (P <0.0001).MiR-150 expression in the PBMC specimens was not significantly different between NSCLC patients and healthy individuals (P=0.260).MiR-150 expression was significantly higher in lung adenocarcinoma patients than in healthy individuals (P=0.001).There was a very strong difference in the expression level of miR-150 between lung adenocarcinoma patients and lung squamous cell caminoma patients (P <0.0001).In receiver operating characteristic curve (ROC) analysis,low expression of miR-143 showed the area under the ROC (AUC) of 0.885 for distinguishing cancer patients from healthy subjects.High expression of miR-150 had an AUC of 0.834 for distinguishing lung adenocarcinoma patients from healthy subjects.High expression of miR-150 had an AUC of 0.951 for distinguishing lung adenocarcinoma from lung squamous cell carcinoma.The miR-150 level was significantly associated with distant metastasis (P=0.014).Conclusions It is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC.Moreover,miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma. Background Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and reduce the mortality.Small non-coding microRNAs (miRNAs) are key components of cancer development and are considered as potential biomarkers for cancer diagnosis and for monitoring treatment.The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in peripheral blood mononuclear cells (PBMC) for the diagnosis of NSCLC.Methods The levels of two mature miRNAs (miR-143 and miR-150) were detected by probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in PBMC of 64 patients with NSCLC and 26 healthy individuals,and the relationship between miR-143 and miR-150 levels and clinical and pathological factors was explored.Results All endogenous miRNAs were present in peripheral blood in a remarkably stable form and detected by RT-qPCR.MiR-143 expression in the PBMC specimens was significantly lower in NSCLC patients than in healthy individuals (P <0.0001).MiR-150 expression in the PBMC specimens was not significantly different between NSCLC patients and healthy individuals (P=0.260).MiR-150 expression was significantly higher in lung adenocarcinoma patients than in healthy individuals (P=0.001).There was a very strong difference in the expression level of miR-150 between lung adenocarcinoma patients and lung squamous cell caminoma patients (P <0.0001).In receiver operating characteristic curve (ROC) analysis,low expression of miR-143 showed the area under the ROC (AUC) of 0.885 for distinguishing cancer patients from healthy subjects.High expression of miR-150 had an AUC of 0.834 for distinguishing lung adenocarcinoma patients from healthy subjects.High expression of miR-150 had an AUC of 0.951 for distinguishing lung adenocarcinoma from lung squamous cell carcinoma.The miR-150 level was significantly associated with distant metastasis (P=0.014).Conclusions It is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC.Moreover,miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2013年第23期4510-4516,共7页 中华医学杂志(英文版)
基金 This study was supported by grants from the National Natural Science Foundation of China (No. 30900247) and the Cooperative Research Project of Foundation and Clinic from Capital Medical University (No. 11JL48).
关键词 MICRORNA carcinoma non-small cell lung DIAGNOSIS microRNA carcinoma,non-small cell lung diagnosis
  • 相关文献

参考文献3

二级参考文献59

  • 1Chng WJ,Lau LG,Yusof N,Mow BM.Targeted therapy in multiple myeloma.Cancer Control 2005; 12:91-104.
  • 2Raab MS,Podar K,Breitkreutz I,Richardson PG,Anderson KC.Multiple myeloma.Lancet 2009; 374:324-339.
  • 3Kumar S.Multiple myeloma:current issues and controversies.Cancer Treat Rev 2010; 36:3-11.
  • 4Kyle RA,Themeau TM,Rajkumar SV,Offord JR,Larson DR,Plevak MF,et al.A long-term study of prognosis in monoclonal gammopathy of undetermined significance.N Engl J Med 2002; 346:564-569.
  • 5Kyle RA,Therneau TM,Rajkumar SV,Larson DR,Plevak MF,Offord JR,et al.Prevalence of monoclonal gammopathy of undetermined significance.N Engl J Med 2006; 354:1362-1369.
  • 6Kuehl WM,Bergsagel PL.Multiple myeloma:evolving genetic events and host interactions.Nat Rev Cancer 2002; 2:175-187.
  • 7Chng WJ,Glebov O,Bergsagel RL,Kuehl WM.Genetic events in the pathogenesis of multiple myeloma.Best Pract Res Clin Haematol 2007; 20:571-596.
  • 8Bi CL,Chng W.Molecular genetics of multiple myeloma.Chichester: John Wiley & Sons, Ltd.; 2010: DOI:10.1002/9780470015902.a0022446.
  • 9Kyle RA,Rajkumar SV.Multiple myeloma.Blood 2008; 111:2962-2972.
  • 10Bartel DP.MicroRNAs:genomics,biogenesis,mechanism,and function.Cell 2004; 116:281-297.

共引文献166

同被引文献50

引证文献13

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部